Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Date:8/8/2008

Keryx to Host Investor Conference Call on Monday, August 11, 2008 at 8:30am

EDT

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the second quarter ended June 30, 2008.

At June 30, 2008, the Company had cash, cash equivalents, investment securities and interest receivable of $34.6 million, as compared to $64.7 million at December 31, 2007. Approximately $10.1 million of the Company's investments, at June 30, 2008, represent auction rate securities which are classified as long-term investments.

The net loss for the second quarter ended June 30, 2008 was $7,697,000, or $0.17 per share, compared to a net loss of $19,460,000, or $0.45 per share, for the comparable quarter in 2007, representing a decrease in net loss of $11,763,000. The decrease in net loss was primarily attributable to a $10,390,000 decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, an $852,000 decrease in expenses related to our other clinical compounds, a $567,000 decrease in non-cash compensation expense related to equity incentive grants, and a $309,000 decrease in other selling, general and administrative expenses, partially offset by a $926,000 decrease in interest and other income.

Commenting on the quarter, Michael S. Weiss, Keryx's Chairman and Chief Executive Officer, said, "During the second quarter, the Company efficiently completed the restructuring which was implemented at the end of the first quarter. We believe that the resulting organization, while lean, possesses the requisite strengths and capabilities necessary to expeditiously move Zerenex and Perifosine forward, as well as to assess additional opportunities which may enhance our product pipeline." Weiss continued, "With respect to our financial health, we expect our cash burn to be approximately $6 million to $8 million for the remaining six months of 2008, and intend to continue to focus our resources on creating value in our product portfolio."

On Monday, August 11, 2008, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's second quarter financial results.

In order to participate in the conference call, please call 1-877-719-9788 (U.S.), 1-719-325-4769 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet, as anticipated, the development timelines for the drug candidates in our pipeline, including Zerenex and KRX-0401; our ability to maintain the projected cash burn rate while successfully completing our clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com

Keryx Biopharmaceuticals, Inc.

Selected Consolidated Financial Data

(Thousands of Dollars, Except Share and Per Share Data)

Statements of Operations Information:

Three Months Ended Six Months Ended

June 30, June 30,

(unaudited) (unaudited)

2008 2007 2008 2007

REVENUE:

License revenue $ 327 $ -- $ 526 $ --

Diagnostic revenue -- 36 -- 66

Service revenue 62 14 62 26

TOTAL REVENUE 389 50 588 92

OPERATING EXPENSES:

Cost of diagnostics sold -- 16 -- 38

Cost of services 14 30 14 62

Research and development:

Non-cash compensation 251 1,178 (729) 2,173

Other research and

development 4,243 15,685 35,071 33,131

Total research and

development 4,494 16,863 34,342 35,304

Selling, general and

administrative:

Non-cash compensation 1,767 1,407 3,484 3,413

Other selling, general and

administrative 2,085 2,394 4,052 5,189

Total selling,

general and administrative 3,852 3,801 7,536 8,602

TOTAL OPERATING EXPENSES 8,360 20,710 41,892 44,006

OPERATING LOSS (7,971) (20,660) (41,304) (43,914)

OTHER INCOME:

Interest and other

income, net 274 1,200 (929) 2,641

NET LOSS $(7,697) (19,460) $(42,233) $(41,273)

NET LOSS PER COMMON SHARE

Basic and diluted $(0.17) $(0. 45) $(0.96) $(0.95)

SHARES USED IN COMPUTING

NET LOSS PER COMMON SHARE

Basic and diluted 44,095,873 43,556,475 43,906,974 43,531,495

Balance Sheet Information:

June 30, December 31,

2008 2007*

(unaudited)

Cash, cash equivalents, interest

receivable and short-term

investment securities $ 24,461 $ 62,386

Long-term investment securities 10,125 2,296

Total assets 39,351 81,061

Accumulated deficit (320,507) (278,274)

Stockholders' equity 5,166 44,422

* Condensed from audited financial statements.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... ... 28, 2017 , ... Starting in May, patients at The Bay Clinic ... (HRV) diagnostic test. , Nerve-Express, originally designed for the Navy in the 1980s, measures ... a patient’s autonomic nervous system (ANS). The ANS controls all the critical unconscious ...
(Date:5/28/2017)... ... May 28, 2017 , ... Florida ... to announce that Sheldon K. Cho, MD, has joined its Winter Haven practice. ... that concentrates on minimally invasive techniques to treat and manage many types of ...
(Date:5/27/2017)... ... ... visiting the dentist? You should go twice per year for checkups, but if you want ... Here are some dental tips to help out: , 1. Brushing Teeth - Brush your ... or a locker at school for a quick brushing after lunch. Use a small brush ...
(Date:5/27/2017)... CA (PRWEB) , ... May 27, 2017 , ... Most ... for concern, but a new study from the Osteoarthritis Initiative shows that ... developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to treat ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... Boston CEO 2017 on May 30th and 31st at The Four Seasons Hotel ... leading executives in the life sciences, offering exclusive access to key decision makers ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... PLEASANTON, Calif. , May 23, 2017 /PRNewswire/ ... world,s most innovative medical devices for pressure ulcer ... at the American Association of Critical Care Nurses, ... Houston May 22-25. The Leaf Patient ... designed specifically for the hospital environment.  The system ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
Breaking Medicine Technology: